JP2005516946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516946A5 JP2005516946A5 JP2003554189A JP2003554189A JP2005516946A5 JP 2005516946 A5 JP2005516946 A5 JP 2005516946A5 JP 2003554189 A JP2003554189 A JP 2003554189A JP 2003554189 A JP2003554189 A JP 2003554189A JP 2005516946 A5 JP2005516946 A5 JP 2005516946A5
- Authority
- JP
- Japan
- Prior art keywords
- present
- tegaserod
- granulation
- formulations
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 2
- 229960002876 Tegaserod Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 description 1
Description
本発明は、従来知られていたのよりも少ない成分を有するテガセロド組成物および造粒を含まない単純な乾燥方法を提供する。本発明の製剤は、より吸湿性が低く、付着の問題を克服し、そして３０分以内の完全または実質的に完全な溶解を提供する。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01403339A EP1321142A1 (en) | 2001-12-21 | 2001-12-21 | Solid pharmaceutical composition for oral administration of Tegaserod |
| EP01403339.3 | 2001-12-21 | ||
| PCT/EP2002/014674 WO2003053432A1 (en) | 2001-12-21 | 2002-12-20 | 5ht4 partial agonist pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005516946A JP2005516946A (ja) | 2005-06-09 |
| JP2005516946A5 true JP2005516946A5 (ja) | 2006-01-19 |
| JP4718776B2 JP4718776B2 (ja) | 2011-07-06 |
Family
ID=8183045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003554189A Expired - Fee Related JP4718776B2 (ja) | 2001-12-21 | 2002-12-20 | ５ｈｔ４部分アゴニスト医薬組成物 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20050106236A1 (ja) |
| EP (2) | EP1321142A1 (ja) |
| JP (1) | JP4718776B2 (ja) |
| KR (1) | KR100980144B1 (ja) |
| CN (1) | CN100464749C (ja) |
| AR (1) | AR037937A1 (ja) |
| AT (1) | ATE320807T1 (ja) |
| AU (1) | AU2002361198B2 (ja) |
| BR (1) | BR0215148A (ja) |
| CA (1) | CA2470668C (ja) |
| CO (1) | CO5640102A2 (ja) |
| CY (1) | CY1105559T1 (ja) |
| DE (1) | DE60210139T2 (ja) |
| DK (1) | DK1458377T3 (ja) |
| EC (1) | ECSP105163A (ja) |
| EG (1) | EG24194A (ja) |
| ES (1) | ES2258171T3 (ja) |
| HU (1) | HU226589B1 (ja) |
| IL (2) | IL162451A0 (ja) |
| MX (1) | MXPA04006157A (ja) |
| MY (1) | MY139546A (ja) |
| NO (1) | NO20042779L (ja) |
| NZ (1) | NZ533585A (ja) |
| PE (1) | PE20030872A1 (ja) |
| PL (1) | PL369509A1 (ja) |
| PT (1) | PT1458377E (ja) |
| RU (1) | RU2322978C2 (ja) |
| SI (1) | SI1458377T1 (ja) |
| TW (1) | TWI260221B (ja) |
| WO (1) | WO2003053432A1 (ja) |
| ZA (1) | ZA200404467B (ja) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL200132B1 (pl) * | 1998-08-21 | 2008-12-31 | Novartis Ag | Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1594517B1 (en) | 2003-01-28 | 2007-06-20 | Microbia, Inc. | Compositions for the treatment of gastrointestinal disorders |
| US20050119328A1 (en) * | 2003-03-25 | 2005-06-02 | Hetero Drugs Limited | Novel crysalline forms of tegaserod maleate |
| US20070065801A1 (en) * | 2003-05-21 | 2007-03-22 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4) |
| PE20050253A1 (es) * | 2003-07-24 | 2005-06-03 | Novartis Ag | Modificaciones estables de maleato de hidrogeno de tegaserod |
| HUE044279T2 (hu) | 2003-09-12 | 2019-10-28 | Amgen Inc | Cinakalcet HCl gyors feloldódású készítménye |
| WO2005058819A2 (en) * | 2003-12-16 | 2005-06-30 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of tegaserod base and salts thereof |
| CZ298399B6 (cs) * | 2005-05-02 | 2007-09-19 | Zentiva, A. S. | Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu) |
| US20070259052A1 (en) | 2006-05-05 | 2007-11-08 | Shire International Licensing B.V. | Assay for lanthanum hydroxycarbonate |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| WO2010078449A2 (en) | 2008-12-31 | 2010-07-08 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US20150336892A1 (en) | 2012-08-21 | 2015-11-26 | Ardelyx, Inc | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP3552630A1 (en) | 2013-04-12 | 2019-10-16 | Ardelyx, Inc. | Nhe3-binding compounds for inhibiting phosphate transport |
| CN104922083B (zh) * | 2015-04-15 | 2017-12-22 | 湖南尔康湘药制药有限公司 | 磺胺嘧啶片及其制备方法 |
| WO2017064538A1 (en) * | 2015-10-16 | 2017-04-20 | Nobel Ilac Sanayii Ve Ticaret A.S. | Pharmaceutical compositions of nilotinib hydrochloride |
| CN110267944B (zh) | 2017-01-09 | 2024-03-08 | 阿德利克斯股份有限公司 | 可用于治疗胃肠道病症的化合物 |
| WO2018129557A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0820586A (ja) * | 1994-07-05 | 1996-01-23 | Sanwa Kagaku Kenkyusho Co Ltd | １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途 |
| IL117438A (en) * | 1995-03-16 | 2001-12-23 | Lilly Co Eli | Indazolecarboxamides, their preparation and pharmaceutical compositions containing them |
| JPH09194374A (ja) * | 1995-11-14 | 1997-07-29 | Taisho Pharmaceut Co Ltd | 消化器疾患治療剤 |
| ATE220543T1 (de) * | 1996-04-23 | 2002-08-15 | Janssen Pharmaceutica Nv | Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| PL200132B1 (pl) * | 1998-08-21 | 2008-12-31 | Novartis Ag | Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu |
| US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| AU3574500A (en) * | 1999-03-25 | 2000-10-16 | Yuhan Corporation | Rapidly disintegrable tablet for oral administration |
| SK287869B6 (sk) * | 1999-08-03 | 2012-02-03 | Icos Corporation | Beta-carboline pharmaceutical compositions |
-
2001
- 2001-12-21 EP EP01403339A patent/EP1321142A1/en not_active Withdrawn
-
2002
- 2002-12-17 EG EG2002121358A patent/EG24194A/xx active
- 2002-12-19 TW TW091136675A patent/TWI260221B/zh not_active IP Right Cessation
- 2002-12-19 AR ARP020105024A patent/AR037937A1/es not_active Application Discontinuation
- 2002-12-20 WO PCT/EP2002/014674 patent/WO2003053432A1/en active IP Right Grant
- 2002-12-20 IL IL16245102A patent/IL162451A0/xx active IP Right Grant
- 2002-12-20 SI SI200230334T patent/SI1458377T1/sl unknown
- 2002-12-20 CN CNB028255321A patent/CN100464749C/zh not_active Expired - Fee Related
- 2002-12-20 AT AT02796711T patent/ATE320807T1/de active
- 2002-12-20 PL PL02369509A patent/PL369509A1/xx not_active Application Discontinuation
- 2002-12-20 MY MYPI20024825A patent/MY139546A/en unknown
- 2002-12-20 RU RU2004122631/15A patent/RU2322978C2/ru not_active IP Right Cessation
- 2002-12-20 AU AU2002361198A patent/AU2002361198B2/en not_active Ceased
- 2002-12-20 US US10/499,721 patent/US20050106236A1/en not_active Abandoned
- 2002-12-20 MX MXPA04006157A patent/MXPA04006157A/es active IP Right Grant
- 2002-12-20 PT PT02796711T patent/PT1458377E/pt unknown
- 2002-12-20 HU HU0402492A patent/HU226589B1/hu not_active IP Right Cessation
- 2002-12-20 CA CA2470668A patent/CA2470668C/en not_active Expired - Fee Related
- 2002-12-20 JP JP2003554189A patent/JP4718776B2/ja not_active Expired - Fee Related
- 2002-12-20 DK DK02796711T patent/DK1458377T3/da active
- 2002-12-20 EP EP02796711A patent/EP1458377B1/en not_active Expired - Lifetime
- 2002-12-20 DE DE60210139T patent/DE60210139T2/de not_active Expired - Lifetime
- 2002-12-20 ES ES02796711T patent/ES2258171T3/es not_active Expired - Lifetime
- 2002-12-20 BR BR0215148-0A patent/BR0215148A/pt not_active IP Right Cessation
- 2002-12-20 NZ NZ533585A patent/NZ533585A/en not_active IP Right Cessation
- 2002-12-20 KR KR1020047009594A patent/KR100980144B1/ko not_active IP Right Cessation
-
2003
- 2003-01-06 PE PE2003000004A patent/PE20030872A1/es not_active Application Discontinuation
-
2004
- 2004-06-07 ZA ZA200404467A patent/ZA200404467B/en unknown
- 2004-06-10 IL IL162451A patent/IL162451A/en not_active IP Right Cessation
- 2004-07-01 NO NO20042779A patent/NO20042779L/no not_active Application Discontinuation
- 2004-07-15 CO CO04067463A patent/CO5640102A2/es not_active Application Discontinuation
-
2006
- 2006-05-04 CY CY20061100579T patent/CY1105559T1/el unknown
-
2008
- 2008-10-07 US US12/287,232 patent/US20090104263A1/en not_active Abandoned
-
2010
- 2010-06-16 EC EC2010005163A patent/ECSP105163A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516946A5 (ja) | ||
| JP2002532112A5 (ja) | ||
| JP2003503454A5 (ja) | ||
| NO20041452L (no) | 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer. | |
| CA2463947A1 (en) | Montelukast granule formulation | |
| NO20053115D0 (no) | Fremgangsmate for fremstilling av 2'-forgrenede nukleosider. | |
| EA200400928A1 (ru) | Диспергируемая во рту фармацевтическая композиция агомелатина | |
| NO20042739L (no) | Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan | |
| NO20024293D0 (no) | Flekkfjernende tyggegummi og konfektblandinger, og fremgangsmåter for fremstilling av de samme | |
| NO20052058D0 (no) | Behandling av influensa. | |
| DK1545230T3 (da) | Belagt tyggegummi | |
| NO20042410L (no) | Sammensetning som omfatter angiopoietinliknende protein 3, ANGPTL3 og fremgangsmate til anvendelse av samme | |
| ID30225A (id) | Tablet matriks yang memungkinkan pelepasan yang diperlama dari gliklazida setelah pemberian secara oral | |
| DE60334379D1 (de) | Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung | |
| AP2004003154A0 (en) | Novel perindopril salt and pharmaceutical compositions containing same. | |
| RS49723B (sr) | Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze | |
| BR0313220A (pt) | Pelìcula de revestimento para comprimidos e cápsulas | |
| IS6956A (is) | Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því | |
| NO20054346L (no) | Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander | |
| NO20000456D0 (no) | Fremgangsmåte for fremstilling av 1,2-dikloretan | |
| DE50309337D1 (de) | Calcium enthaltende süssigkeit | |
| EA200600173A1 (ru) | Диспергируемая во рту фармацевтическая композиция антитромботического соединения | |
| NO20035642L (no) | Fremgangsmate for fremstilling av derivater av 1,5-diaryl-3-trifluormetyl-delta2-pyrazoliner som er racemisk og enantiomerisk rene | |
| NO20043665L (no) | Fremgangsmate for fremstilling av 6.alfa.,9.alfa-difluor-17.alfa.-(1-okso-propoksy-11.beta.-hydroxy-16.alfa.-metyl-3-okso-androst-1,4-dien-17.beta.-tiokarboksylsyre | |
| JP2004537288A5 (ja) |